Welcome to our dedicated page for ACTUATE THERAPEUTICS SEC filings (Ticker: ACTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Actuate Therapeutics, Inc. filings document a clinical-stage oncology issuer with Nasdaq-listed common stock and emerging growth company status. Registration statements and capital-structure disclosures cover the company's common stock offering, security terms, and public-company reporting framework.
Actuate's 8-K and proxy filings record material events, Regulation FD clinical disclosures for elraglusib in metastatic pancreatic ductal adenocarcinoma, material agreements, shareholder voting matters, board composition, director elections, auditor ratification, governance matters, and risk-related disclosures tied to its biopharmaceutical development program.
ACTUATE THERAPEUTICS, INC. director and ten percent owner Aaron G.L. Fletcher received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $2.4200 per share, expire on May 21, 2036, and will vest in full on the first anniversary of the grant date. Following this grant, Fletcher holds 15,000 stock options directly.
Actuate Therapeutics reports a Q1 2026 net loss of $5,625,749, modestly improved from $6,317,024 a year earlier, as it advances lead cancer drug elraglusib. Research and development expenses were $2,565,244 and general and administrative costs were $3,140,712, both roughly stable to slightly lower year over year.
Cash and cash equivalents were $8,134,004 with working capital of $3,797,551, and management expects this to fund operations only into July 2026, leading to a conclusion of substantial doubt about continuing as a going concern. The company is relying on a $100M at-the-market facility and a separate $50M committed equity facility for future funding.
Clinically, updated Phase 2 data in metastatic pancreatic cancer showed median overall survival of 10.1 months for elraglusib plus standard therapy versus 7.2 months for control, with higher 12- and 24-month survival rates, supporting plans for an oral formulation and additional studies, subject to securing more capital.
Actuate Therapeutics filed an 8-K to share that the FDA has cleared an Investigational New Drug application for an oral tablet formulation of elraglusib, allowing a Phase 1/2 study in advanced solid tumors, including metastatic melanoma, NSCLC, colorectal and pancreatic cancers, with initiation planned for the second half of 2026.
The company is shifting its elraglusib program from an IV to an oral formulation after a Phase 2 trial in metastatic pancreatic ductal adenocarcinoma showed improved overall survival when IV elraglusib was added to gemcitabine plus nab-paclitaxel. Actuate also highlights nonclinical and early clinical data supporting use in RAS-driven cancers and rare pediatric cancers such as Ewing sarcoma and neuroblastoma, and notes potential value from a future pediatric Priority Review Voucher.
At the same time, the exhibits reiterate that Actuate’s financial condition raises substantial doubt about its ability to continue as a going concern and that it needs additional capital to fund operations beyond mid-2026, which could force delays or reductions in its development programs if financing is not obtained.
ACTUATE THERAPEUTICS, INC. director Dr. Martin H. Huber Jr. reported an initial holding of non-qualified stock options on Common Stock. He was granted 30,000 stock options upon joining the Board of Directors, with an exercise price of $3.00 per share and expiration on May 1, 2036.
The grant vests in three equal installments on the first, second, and third anniversaries of the grant date, contingent on his continued service. Following this grant, he holds derivative rights over 30,000 underlying shares through these options, representing equity-based compensation rather than an open-market trade.
Actuate Therapeutics, Inc. appointed Martin H. Huber, MD, as an independent director and expanded its Board from seven to eight members. He will serve as a Class III director until the 2027 annual meeting and join the Nominating and Corporate Governance Committee.
Dr. Huber will participate in the non-employee Director Compensation Program, including stock options to purchase 30,000 common shares vesting over three years and an annual cash retainer of $44,000, paid quarterly. A separate consulting agreement provides a $3,000 quarterly fee for additional R&D advisory services.
The accompanying press release highlights Actuate’s focus on developing elraglusib for difficult-to-treat cancers and reiterates risk factors, including that its financial condition raises substantial doubt about its ability to continue as a going concern without additional capital beyond the second quarter of fiscal 2026.
Voss Capital and affiliated entities report beneficial ownership stakes in Actuate Therapeutics. The filing states that Voss Capital (through managed accounts and funds) may be deemed to beneficially own 1,814,263 shares, representing approximately 7.65% of Actuate's outstanding common stock. The report breaks this total into holdings including Voss Value Master Fund: 300,000 shares, Voss Value-Oriented Special Situations Fund: 50,000 shares, and Voss Advisors GP (as GP): 350,000 shares. Shares outstanding are reported as 23,709,943 as of March 25, 2026.
Actuate Therapeutics, Inc. is holding its 2026 virtual annual meeting of stockholders on May 21, 2026 at 11:00 a.m. EDT to elect two Class II directors and ratify Crowe LLP as independent auditor for 2026.
Stockholders of record as of March 24, 2026, holding 23,704,691 common shares, may vote online, by phone, mail or during the webcast. The proxy also details corporate governance practices, committee structures and 2025 executive pay, including salary, cash bonuses and equity awards under the 2024 Stock Incentive Plan.
Actuate Therapeutics reported that President and CEO Daniel M. Schmitt received a grant of employee stock options covering 237,000 shares of common stock. The options have an exercise price of $2.49 per share and expire on April 1, 2036.
All 237,000 options are shown as held directly following the transaction. According to the grant terms, 25% of the options will vest on April 1, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months.
ACTUATE THERAPEUTICS, INC. reported that Chief Operating Officer Andrew Paul Mazar received an employee stock option grant for 105,000 options to buy common stock at an exercise price of $2.49 per share.
The options expire on April 1, 2036. According to the vesting terms, 25% of the grant will vest on April 1, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months. After this grant, he holds 105,000 derivative securities directly.